Dow Up1.33% Nasdaq Up1.33%

Cascadian Therapeutics, Inc. (CASC)

-NasdaqGS
0.94 Down 0.05(5.14%) 4:00PM EDT
ProfileGet Profile for:
Cascadian Therapeutics, Inc.
2601 Fourth Avenue
Suite 500
Seattle, WA 98121
United States - Map
Phone: 206-801-2100
Fax: 206-801-2101
Website: http://www.cascadianrx.com

Details 
Index Membership:N/A
Sector:Industrial Goods
Industry:Farm & Construction Machinery
Full Time Employees:53

Business Summary 

Cascadian Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of cancer. Its clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, which is in two Phase 1b trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. The company is also developing Checkpoint kinase 1, a protein kinase in pre-clinical studies to inhibit tumor growth as single agents. In addition, it focuses on researching on Protocells, which are nanoparticles designed to enable the targeted delivery of various therapeutic agents, including nucleic acids, proteins, peptides, and small molecules, as well as to develop product candidates for the treatment of cancer. The company has a research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; Celldex Therapeutics, Inc. on a combined clinical trial of ONT-10 and varlilumab; and Adimab LLC for the discovery of novel antibodies against undisclosed immunotherapy targets in oncology. The company was formerly known as Oncothyreon Inc. and changed its name to Cascadian Therapeutics, Inc. in June 2016. Cascadian Therapeutics, Inc. was founded in 1985 and is headquartered in Seattle, Washington.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Cascadian Therapeutics, Inc.

Corporate Governance 
Cascadian Therapeutics, Inc.’s ISS Governance QuickScore as of Apr 1, 2013 is 2. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 2; Compensation: 5.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Ms. Julia M. Eastland M.B.A., 52
Chief Financial Officer, VP of Corp. Devel. and Sec.
376.00K0.00
Mr. Gary Christianson PE, 61
Chief Operating Officer
395.00K0.00
Dr. Scott Robert Peterson Ph.D., 54
Chief Scientific Officer
398.00K0.00
Mr. Scott D. Myers , 50
Chief Exec. Officer, Pres and Director
N/AN/A
Mr. Terry Harris ,
Director of HR
N/AN/A
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders